Advanced search×

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Masahiro M Fukuoka, Yi-Long YL Wu, Sumitra S Thongprasert, Patrapim P Sunpaweravong, Swan-Swan SS Leong, Virote V Sriuranpong, Tsu-Yi TY Chao, Kazuhiko K Nakagawa, Da-Tong DT Chu, Nagahiro N Saijo, Emma L EL Duffield, Yuri Y Rukazenkov, Georgina G Speake, Haiyi H Jiang, Alison A AA Armour, Ka-Fai KF To, James Chih-Hsin JC Yang, and Tony S K TS Mok

J Clin Oncol 29(21):2866-74 (2011) PMID 21670455

The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status.

DOI: 10.1200/JCO.2010.33.4235
Version: za2963e q8zac q8zb1 q8zcf q8zde q8zec q8zf0 q8zgb

Similar articles you may find interesting…

  1. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
    John F Smyth, Charlie Gourley, ... Simon P Langdon

    Clin Cancer Res 13(12):3617-22 (2007) PMID 17575226

    This is the first study of a hormonal agent in a preselected group of ER-positive ovarian cancer patients. A signature of predictive markers, including low HER2 expression, predicts response....
  2. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Maria M Stendahl, Lisa L Rydén, ... Karin K Jirström

    Clin Cancer Res 12(15):4614-8 (2006) PMID 16899609

    Adjuvant tamoxifen improved recurrence-free and overall survival for premenopausal patients with tumors showing >75% PR-positive nuclei. No effect could be shown in tumors with fewer PR-positive nuclei. The PR was a stronger predictor of treatment response than the ER. Based on these findings, we su...
  3. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression...
    Giuseppe G Viale, Meredith M MM Regan, ... Alan S AS Coates

    Audio, Transactions of the IRE Professio... 26(9):1404-10 (2008) PMID 18349391

    Both receptors displayed a bimodal distribution, with substantial proportions showing no staining (receptor absent) and most of the remainder showing a high percentage of stained cells. Chemo-endocrine therapy yielded DFS superior to endocrine therapy alone for patients with receptor-absent tumors,...